BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 23991844)

  • 1. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
    Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
    J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.
    Tamura K; Aoyagi M; Wakimoto H; Ando N; Nariai T; Yamamoto M; Ohno K
    J Neurosurg; 2010 Aug; 113(2):310-8. PubMed ID: 20205512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
    Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
    J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
    He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
    Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell marker CD133 affects clinical outcome in glioma patients.
    Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
    Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.
    Saito N; Aoki K; Hirai N; Fujita S; Iwama J; Hiramoto Y; Ishii M; Sato K; Nakayama H; Harashina J; Hayashi M; Izukura H; Kimura H; Ito K; Sakurai T; Yokouchi Y; Oharazeki T; Takahashi K; Iwabuchi S
    Brain Tumor Pathol; 2015 Jul; 32(3):176-83. PubMed ID: 25665548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
    Li MW; Niu CS
    Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
    Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
    Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
    Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
    Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
    Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
    Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
    Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
    Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
    Huang Q; Zhang QB; Dong J; Wu YY; Shen YT; Zhao YD; Zhu YD; Diao Y; Wang AD; Lan Q
    BMC Cancer; 2008 Oct; 8():304. PubMed ID: 18940013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
    Dahlrot RH
    Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD133-positive stem cells.
    Bian EB; Li J; Zhao B
    J Neurosurg; 2014 Apr; 120(4):1011-2. PubMed ID: 24506246
    [No Abstract]   [Full Text] [Related]  

  • 16. Rac1+ cells distributed in accordance with CD 133+ cells in glioblastomas and the elevated invasiveness of CD 133+ glioma cells with higher Rac1 activity.
    Zhang B; Sun J; Yu SP; Chen C; Liu B; Liu ZF; Ren BC; Ming HL; Yang XJ
    Chin Med J (Engl); 2012 Dec; 125(24):4344-8. PubMed ID: 23253699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133-positive stem cells. Response.
    Tamura K; Aoyagi M
    J Neurosurg; 2014 Apr; 120(4):1012. PubMed ID: 24809085
    [No Abstract]   [Full Text] [Related]  

  • 18. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.
    Beier D; Wischhusen J; Dietmaier W; Hau P; Proescholdt M; Brawanski A; Bogdahn U; Beier CP
    Brain Pathol; 2008 Jul; 18(3):370-7. PubMed ID: 18371181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of PKCδ signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment.
    Kim MJ; Kim RK; Yoon CH; An S; Hwang SG; Suh Y; Park MJ; Chung HY; Kim IG; Lee SJ
    J Cell Sci; 2011 Sep; 124(Pt 18):3084-94. PubMed ID: 21878493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
    Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.